Observational study investigating the efficacy and safety of fulvestrant + CDK4 / 6 inhibitor as a primary endocrine therapy for hormone receptor-positive, HER2-negative advanced/metastatic breast cancer - Observational study investigating the efficacy and safety of fulvestrant + CDK4 / 6 inhibitor as a primary endocrine therapy for hormone receptor-positive, HER2-negative advanced/metastatic breast cancer

Breast Surgery, Yokkaichi Municipal Hospital0 个研究点目标入组 30 人开始时间: 2021年4月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Recurrence during postoperative hormone therapy or within 1 year from completion of treatment 2) Known uncontrolled or symptomatic central nervous system metastases 3) Patients with advanced symptomatic visceral spread that are at risk of life threatening complication in the short term 4) Prior endocrine therapy for advanced/metastatic breast cancer 5) Known interstitial lung disease on imaging 6) Known uncontrolled infection 7) Current pregnancy and lactation or possibility of pregnancy 8) Known drug allergy to any of study drugs 9) Assessment by investigator that subject unable to comply with protocol

发起方

Breast Surgery, Yokkaichi Municipal Hospital